Cyclic 3,5-adenosine monophosphate (cAMP) and cyclic 3,5-guanosine monophosphate (cGMP) are important second messengers that play a central role in mediating a variety of functional responses to hormones and other cellular transmitters (1-4). Sensitivity of the physiological processes regulated by cyclic nucleotides requires precise and rapid regulation of the level of these second messengers according to the requirements of the physiological status of the cell. Precise modulation of the phosphodiesterase (PDE) function is critical for maintaining cyclic nucleotide levels within a narrow concentration range. Due to their key role in the regulation of physiological processes, inhibitors of PDEs can be used as therapeutic tools for various diseases. Relatively less emphasis, however, has been placed on the development of agents that interfere with the 103 Acta Pharm. 61 (2011) 103-113 
catabolism of cAMP and cGMP via inhibition of phosphodiesterase. A variety of nitrogen and sulfur containing heterocycles are reported to inhibit PDE (5) (6) (7) (8) (9) (10) . Quinazolines and condensed quinazoline such as hoquizil, prazosin and buqineran, possess PDE inhibitory (11, 12) antimicrobial (13) , antiinflammatory (14) , anticonvulsant (15) and antihypertensive (16) activity (Fig. 1) . Based on these observations, a hypothetical model has been proposed, taking into account the following broad objectives: to develop new fused heterocycles expected to exert PDE inhibitory activity similar to that of theophylline.
Based on this approach, we attempted to synthesize 6,7,8,9-tetrahydro-5H-5-(2'-hydroxyphenyl)-2-(4'-substituted benzylidine)thiazolo(2,3-b)quinazolin-3(2H)-one (4a-j) and 6,7,8,9-tetrahydro-5H-5-(2'-hydroxyphenyl)-2-(4'-substituted benzylidine)-3-(4-nitrophenylamino)thiazoloquinazolines (5a-j) analogues. The PDE inhibitory activity for all title compounds (4a-j and 5a-j) was tested using a standard technique (4) . EXPERIMENTAL Bovine heart phosphodiesterase sample was obtained from Sigma (India) and theophylline, as a reference compound, from German Remedies (India).
Melting points were taken in an open capillary tube and were uncorrected. IR spectra were recorded in KBr pellets (ABB Bomem FT-IR spectrometer MB 104, ABB Limited, India). The 1 H-NMR spectra were recorded in CDCl 3 (Bruker 400 NMR spectrometer, IET Limited) with TMS as internal reference. Mass spectral data were recorded with a quadrupol mass spectrometer (Shimadzu GC MS QP 5000, Japan). Microanalyses were performed using a Vario EL V300 elemental analyzer (Elemental Analysensysteme GmbH, Germany). The purity of the compounds was checked by TLC on pre-coated SiO 2 gel (HF 254 ) aluminium plates (Merck, USA) using ethyl acetate/benzene (1:3) and visualized in a UV chamber. Physico-chemical and spectral data results of these compounds are shown in Table I . 
Syntheses
The target novel thiazoloquinazoline derivatives were synthesized by the previously reported method (17) . The key intermediate and target compounds are illustrated in Scheme 1. (1) . -Equimolar quantities of each cyclohexanone (0.039 mol) and salicylaldehyde (0.039 mol) were taken in a beaker; to this, sodium hydroxide solution was added to make the solution alkaline. This was shaken and kept aside. The solid thus obtained was filtered, washed with water and recrystallized from absolute ethanol. 3,4,5,6,7,8-hexahydroquinazolin-2-thione (2) . -A mixture of 2-hydroxybenzylidine cyclohexanone (1) (0.039 mol), thiourea (0.03 mol) and potassium hydroxide (2.5 g) in 95 % ethanol (100 mL) was heated under reflux for 3 h. The reaction mixture was concentrated to half its volume, diluted with water, then acidified with glacial acetic acid and kept overnight. The solid thus obtained was filtered, washed with water and recrystallized from ethanol to give 2. 
2-Hydroxybenzylidine cyclohexanone

4-Hydroxy phenyl
6,7,8,9-Tetrahydro-5H-5-(2'-hydroxyphenyl)thiazolo(2,3-b)quinazolin-3(2H)-one (3).
-Chloroacetic acid (0.096 mol) was melted on a water bath and 2 (0.009 mol) was added portionwise to maintain homogeneity. The homogeneous mixture was heated on a water bath for 30 min and kept overnight. The solid thus obtained was washed with water and recrystallized from ethanol to give 3.
6,7,8,9-Tetrahydro-5H-5-(2'-hydroxyphenyl)-2-(4'-substituted benzylidine)thiazolo(2,3-b) quinazolin-3(2H)-ones (4a-j).
-A mixture of 3 (0.002 mol), substituted benzaldehyde (0.002 mol) and anhydrous sodium acetate (0.002 mol) in glacial acetic acid (10 mL) was heated under reflux for 4 h. The reaction mixture was kept overnight and the solid thus separated was filtered, washed with water and recrystallized from ethanol to furnish 6,7,8,9-tetrahydro-5H-5-(2'-hydroxyphenyl)-2-(4'-substituted benzylidine) thiazolo (2,3-b)quinazolin-3(2H)-ones (4a-j).
6,7,8,9-Tetrahydro-5H-5-(2'-hydroxyphenyl)-2-(4'-substituted benzylidine)-3-(4-nitrophenylamino)thiazoloquinazolines (5a-j).
-A reaction mixture of the respective quinazolin-3(2H)-one 4a-j (0.004 mol) was dissolved in (0.004 mol) thionyl chloride. To this, DMF (0.004 mol) was added to get chloro derivates. The reaction mixture was then coupled with p-nitroanilines (0.004 mol) in DMF at 80°C for 3 h. After the mixture was cooled, the precipitate was filtered, recrystallized from ethanol, and dried to give the target compounds 6,7,8,9--tetrahydro-5H-5-(2'-hydroxyphenyl)-2-(4'-substituted benzylidine)-3-(4-nitrophenylamino)thiazoloquinazolines (5a-j).
PDE inhibition assay
Inhibition of bovine heart phosphodiesterase was determined by the known method (2) . PDE activity was calculated by measuring the production of inorganic phosphates in the presence of an excess of 5-nucleotidase. Each sample contained 1 mmol L -1 cAMP, 3 mmol L -1 MgSO 4 , 5-nucleotidase (0.02 units mL -1 ) and bovine heart phosphodiesterase (0.002 units mL -1 ), and appropriate concentration of the test compound in ethanol and Tris-HCl buffer (pH 7.5, 50 mmol L -1 ), in a final volume of 1 mL. The reagents comprising 0.4 mL acid molybdate solution, 0.4 mL Elon reducing agent, and 1.0 mL H 2 O, to give a final volume of 3.0 mL, were mixed in an incubation vessel, and the reaction was initiated by addition of cAMP and allowed to proceed for 20 min over a 30°C water bath. The reaction was terminated by addition of 0.2 mL 5 % trichloroacetic acid. The solution was then vortexed and centrifuged at 800´g for 10 min. Color was allowed to develop for 20 min and absorbance was measured at 660 nm. The results given in Table II are expressed as the concentration of inhibitor giving 50 % inhibition (IC 50 ) of the cAMP--dependent PDE activity. The IC 50 value was determined from plot of percentage inhibition vs. varying concentration of the inhibitor compounds 4a-j and 5a-j. To validate the enzyme assay method, the IC 50 value of theophylline as a standard inhibitor was also determined.
RESULTS AND DISCUSSION
Chemistry
The series of heterocycles 4a-j and 5a-j were synthesized by the reaction of 3 with appropriate aromatic aldehyde and p-nitroaniline in the presence of anhydrous sodium acetate and DMF as it is presented in Scheme 1. The IR, 1 H NMR, mass spectroscopy and elemental analyses for the new compounds were in accord with the assigned structures. The IR spectra of compounds 4a-j showed stretching bands of the keto group at 1715-1740 cm -1 . In 5a-j, stretching and bending NH bands of thiazoloquinazoline moiety appear at 3300-3400 and 1300-1350 cm -1 , respectively. The recorded IR spectra of compounds 5a-j showed no keto group bands. This clearly envisages that the keto group of 4a-j is converted into secondary NH. In 5a-j, the NH signal of 3- (4- 1 H NMR spectra of final compounds conform with the secondary NH proton in thiazoloquinazoline moiety. This clearly envisages that thiazole-3-one moiety was involved in 3-(4-nitrophenyl)amino formation. Mass spectra showed accurate molecular ion peaks at m/z 300, 478 and 528 for 3, 4h and 5e, resp. All these facts clearly demonstrated that the 3 rd position of keto group in thiazole ring was converted into secondary amino group, as indicated in Sheme 1 and conforming with the proposed structures 5a-j.
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PDE inhibition activity
The target compounds were evaluated for their ability to inhibit bovine heart phosphodiesterase with theophylline chosen as a standard for comparison (Table II) . All the compounds were found to exhibit PDE inhibitory activity. Despite the fact that this assay is less sensitive compared to radioisotope PDE assays and likely to underestimate the relative inhibitory potencies of the test compounds, the results of this evaluation indicate that the quinazoline derivatives are still more potent inhibitors of PDE than theophylline.
Compounds having thiazolo(2,3-b)quinazolin-3(2H)-one (4a-j) and thiazoloquinazoline (5a-j) ring systems were all found to exhibit promising PDE inhibitory activity with IC 50 in the range 1.34-2.64 (±0.09) mmol L -1 and activity relative to theophylline of 0.84-1.47. Among them 6,7,8,9-tetrahydro-5H-5-(2'-hydroxyphenyl)-2-(4'-chlorobenzyline)-3-(4-nitrophenylamino)thiazoloquinazoline (5f) was found to be most potent, with relative activity of 0.8 compared to the standard, whereas for both compounds 6,7,8,9-tetrahydro-5H-5-(2'-hydroxyphenyl)-2-(4'-fluorobenzylidine)-3-(4-nitrophenylamino)thiazoloquinazoline (5e) and 6,7,8,9-tetrahydro-5H-5-(2'-hydroxyphenyl)-2-(4'-nitrobenzylidine)--3-(4-nitrophenylamino)thiazoloquinazoline (5j) relative reactivity was found to be 0.87.
The electronic nature of the substituent groups at second positions in thiazole nucleus led to significant variation in PDE inhibitory activity. In both series the presence of an electron-withdrawing group (chloro, fluoro, nitro, bromo) in the thiazoloquinazoline nucleus resulted in higher activity. For example, 4-nitrophenyl amino substitution in thiazoloquinazoline nucleus (5a-j) increased activity; the order of activity was Cl > F > NO 2 > Br > electron donating group. Compound 5f, 5e, 5j and 5g showed higher activity than the reference drug theophylline.
CONCLUSION
In summary, the present study has demonstrated that fused thiazoloquinazolines are novel inhibitors of phosphodiesterase and may potentially act as smooth muscle relaxatory agents. Further work is in progress to estabilish this observation in different animal models and find selective inhibitors of PDE 4, which may impact strategies for bronchodilator activity.
